Please note: This is for information only.

Refer to local guidelines for treatment recommendations

  • Voriconazole is a synthetic antifungal agent belonging to the azole group. It inhibits the enzyme 14-alpha lanosterol and thereby disrupts the synthesis of ergosterol in the fungal cell membrane.
  • Available in oral and intravenous formulations.
  • Oral bioavailability is high (~96%) and tissue distribution is extensive.
  • Elimination is by hepatic metabolism; no dose adjustment is required in patients with renal impairment, however, IV preparation should be avoided in patients with renal impairment as accumulation of the vehicle may occur
  • Usual Adult dose: 400 mg every 12 hours for 2 doses then 200 mg every 12 hours (assuming body weight > 40 Kg).
  • Numerous drug interactions.

Main indications

  • Microbiology advice – restricted agent.
  • Consultant approval as part of the haematology neutropenic sepsis protocol.

Active against most strains of:

  • Candida spp.
  • Aspergillus spp.
  • Cryptococcus neoformans (inc. fluconazole-resistant strains)
  • Dimorphic pathogens such as Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum
  • Fusarium spp.
  • Scedosporium spp.
  • Penicillium marneffei
  • Not active against most strains of:
  • Zygomycetes (Mucor, Rhizpus and Absidia).